Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5)

被引：0
|
作者：
Laux, L.
Devinsky, O.
Miller, I
Nabbout, R.
Zolnowska, M.
Wright, S.
Roberts, C.
机构：
来源：
ANNALS OF NEUROLOGY | 2018年 / 84卷
关键词：
Epilepsy; Rare Diseases;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
47
引用
收藏
页码：S344 / S344
页数：1
相关论文
共 50 条
  • [31] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, Andrew
    Guttman, Emma
    Hussain, Iftikhar
    Chen, Zhen
    Mina-Osorio, Paola
    Rossi, Ana Beatris
    Bansal, Ashish
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB141 - AB141
  • [32] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, A.
    Guttman-Yassky, E.
    Hussain, I.
    Worrell, R.
    Chen, Z.
    Mina-Osorio, P.
    Rossi, A. B.
    Bansal, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 29 - 31
  • [33] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, A.
    Guttman-Yassky, E.
    Hussain, I.
    Chen, Z.
    Mina-Osorio, P.
    Rossi, A. B.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E96 - E96
  • [34] Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial
    Thiele, Elizabeth A.
    Bebin, E. Martina
    Filloux, Francis
    Kwan, Patrick
    Loftus, Rachael
    Sahebkar, Farhad
    Sparagana, Steven
    Wheless, James
    EPILEPSIA, 2022, 63 (02) : 426 - 439
  • [35] Long-term safety and efficacy of add-on cannabidiol for treatment of seizures associated with tuberous sclerosis complex in an open-label extension
    Kwan, Patrick
    Thiele, Elizabeth A.
    Bebin, E. Martina
    Filloux, Francis
    Jansen, Floor E.
    Loftus, Rachael
    Sahebkar, Farhad
    Sparagana, Steven
    Wheless, James
    EPILEPSIA, 2021, 62 : 145 - 146
  • [36] Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: An open-label extension trial
    McConville, B
    Carrero, L
    Sweitzer, D
    Potter, L
    Chaney, R
    Foster, K
    Sorter, M
    Friedman, L
    Browne, K
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (01) : 75 - 82
  • [37] Long-Term Efficacy and Safety with Lanreotide Autogel/ Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies
    Phan, A. T.
    Pavel, M.
    Caplin, M.
    Wolin, E. M.
    Mirakhur, B.
    Massien, C.
    Liyanage, N.
    Lowenthal, Pittman S.
    Ruszniewski, P.
    NEUROENDOCRINOLOGY, 2017, 105 : 207 - 207
  • [38] Long-Term Efficacy and Safety of Sparsentan in FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)
    Srivastava, Tarak
    Tesar, Vladimir
    Campbell, Kirk N.
    Rheault, Michelle N.
    Komers, Radko
    Murphy, Edward
    Trachtman, Howard
    Gesualdo, Loreto
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 33 - 33
  • [39] Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: Interim results of an open-label extension study
    Ng, Yu-Tze
    Conry, Joan
    Paolicchi, Juliann
    Kernitsky, Lydia
    Mitchell, Wendy
    Drummond, Rebecca
    Isojarvi, Jouko
    Lee, Deborah
    Owen, Randall
    EPILEPSY & BEHAVIOR, 2012, 25 (04) : 687 - 694
  • [40] LONG-TERM SPARSENTAN TREATMENT IN YOUNG PATIENTS WITH FSGS IN THE DUET OPEN-LABEL EXTENSION (OLE)
    Lieberman, Kenneth
    Paredes, Ana
    Srivastava, Tarak
    Komers, Radko
    Murphy, Edward
    Prasad, Andy
    Trachtman, Howard
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S94 - S95
12345